Physician profile
Brian Dixon
NPI 1588635593
$11,514.89
in general payments reported to CMS, 2019-2025
44 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $816 · 2021: $2,073 · 2022: $2,092 · 2023: $1,559 · 2024: $2,054 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,963.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,736.12 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Novo Nordisk INC | $1,446.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,285.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,167.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $579.55 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $479.42 | 2019-2025 | Repatha |
| Astellas Pharma US INC | $438.20 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $385.22 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $382.37 | 2019-2023 | |
| Amarin Pharma, INC. | $312.47 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.55 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $282.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $277.14 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $266.33 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.